Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $3.7 million.

  • Theravance Biopharma's Treasury Shares fell 1273.02% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 1273.02%. This contributed to the annual value of $4.0 million for FY2024, which is 100.76% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Treasury Shares is $3.7 million, which was down 1273.02% from $4.1 million recorded in Q2 2025.
  • Theravance Biopharma's Treasury Shares' 5-year high stood at $15.6 million during Q3 2023, with a 5-year trough of $3.1 million in Q1 2024.
  • Its 5-year average for Treasury Shares is $6.9 million, with a median of $4.5 million in 2024.
  • In the last 5 years, Theravance Biopharma's Treasury Shares surged by 6728.05% in 2021 and then crashed by 7258.68% in 2024.
  • Theravance Biopharma's Treasury Shares (Quarter) stood at $8.4 million in 2021, then surged by 52.49% to $12.7 million in 2022, then plummeted by 68.63% to $4.0 million in 2023, then decreased by 1.01% to $4.0 million in 2024, then dropped by 5.53% to $3.7 million in 2025.
  • Its Treasury Shares was $3.7 million in Q3 2025, compared to $4.1 million in Q2 2025 and $4.5 million in Q1 2025.